

ONE HUNDRED NINETEENTH CONGRESS
Congress of the United States
House of Representatives
COMMITTEE ON ENERGY AND COMMERCE
2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115

Majority (202) 225-3641
Minority (202) 225-2927

October 27, 2026

The Honorable Orice Williams Brown
Acting Comptroller General
U.S. Government Accountability Office
441 G Street NW
Washington, DC 20548

Dear Acting Comptroller General Brown:

I write to request that the Government Accountability Office (GAO) conduct a review of TrumpRx.gov (TrumpRx), a federal government platform launched in February 2026 that directs certain patients to discounted prescription drug products. At a time when Americans are facing skyrocketing prices on everything, including health care costs, it is important that we ensure any claims of making prescription drugs more affordable are based in reality.

The Trump Administration has claimed that TrumpRx has generated substantial new savings for American patients.¹ However, it has failed to disclose critical information allowing the public to scrutinize those claims. On February 5, 2026, the Administration announced a series of deals with pharmaceutical manufacturers where the companies agreed to advertise certain drug products on TrumpRx at prices “in line with the lowest paid by other developed nations.”² Congressional Democrats requested that the President provide those agreements to Congress, which he has not done.³ Two heavily redacted agreements have been produced in Freedom of Information Act litigation, but they do not provide the full terms of companies’ participation in TrumpRx, nor do they suggest how the Administration might substantiate its

¹ See, e.g., The White House, *Trump Extends Most Favored Nation Pricing to Every Medicaid Program in America* (Sept. 18, 2026) (press release); The White House, *President Trump Launches TrumpRx.gov, Delivering Massive, Immediate Savings to Millions of Americans* (Feb. 6, 2026) (press release).

² The White House, *Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients* (Feb. 5, 2026) (<https://www.whitehouse.gov/fact-sheets/2026/02/fact-sheet-president-donald-j-trump-launches-trump-rx-gov-to-bring-lower-drug-prices-to-american-patients/>).

³ Letter from Rep. Frank Pallone, Jr., Ranking Member, House Committee on Energy and Commerce, Rep. Richard E. Neal, Ranking Member, House Committee on Ways and Means, Rep. Robert C. “Bobby” Scott, Ranking Member, House Committee on Education and Workforce, and Sen. Ron Wyden, Ranking Member, Senate Committee on Finance, to President Donald J. Trump (Mar. 5, 2026).

claims of substantial savings through TrumpRx.⁴ At the same time, the Trump Administration has not publicly disclosed how or if it is monitoring patient safety concerns associated with TrumpRx, including potential disruptions to continuity of care for its users.

While the Trump Administration has made sweeping statements about TrumpRx's success, claiming major discounts on certain medications and \$700 million in savings, the failure to disclose key information about the platform has prevented Americans and Congress from evaluating whether TrumpRx actually offers any meaningful financial benefit.⁵ There is no transparency into this process and the Administration continues to obstruct congressional oversight on this topic, making it impossible to evaluate the real impacts of these secretive agreements and whether they are actually making prescription drugs more affordable for the American people.

I request that GAO analyze whether and how the platform tracks usage and whether it is possible to calculate what, if any, savings it has provided for Americans. Specifically, I request that GAO examine the following:

1. How many individual transactions have been fulfilled through TrumpRx?
2. How many unique consumers have used TrumpRx to purchase prescription drugs? Of those, how many were:
 - a. Privately insured;
 - b. Insured through a publicly funded program, such as Medicaid or Medicare Part D; or,
 - c. Uninsured.
3. Which drugs are most and least frequently purchased through TrumpRx? For each drug, please identify the total number of transactions and the number of unique consumers.
4. What data and methodology have been used to determine whether the advertised price on TrumpRx is "in line with the lowest paid by other developed nations?"

⁴ *Public Citizen FOIA Reveals That Pharma, Not Patients Are Favored In Trump's Drug Pricing Deals*, Public Citizen (Sept. 19, 2026); *Most Favored Nation Drug Pricing Agreement Between the Department of Health and Human Services and Pfizer Inc.* (Feb. 23, 2026) (https://www.citizen.org/wp-content/uploads/HHS-Pfizer-MFN-Agreement-Final_2.17.26_HHS-Pfizer-Signed-Redacted-Copy.pdf); *Most Favored Nation Drug Pricing Agreement Between the Department of Health and Human Services and Eli Lilly Inc.* (Feb. 23, 2026) (https://www.citizen.org/wp-content/uploads/HHS-Eli-Lilly-MFN-Agreement-Final_2.17.2026_Fully-Executed-Redacted-Copy.pdf).

⁵ See note 1.

- a. How many drugs listed on TrumpRx are priced higher than the lowest prices “paid by other developed nations,” and by how much?
5. How many drugs on TrumpRx are subject to use restrictions, including restrictions based on insurance coverage, quantity, dosage, or fulfillment mechanisms?
6. How many drugs on TrumpRx are available at lower prices through external purchasing options, including insurance coverage, generic or biosimilar alternatives, or manufacturer discount programs not presented on TrumpRx?
7. What data and methodology supports the Administration’s claim of \$700 million in savings for American patients? Is that methodology consistent with established approaches?
8. How many discounts advertised on TrumpRx resulted from direct negotiation between the Trump Administration and pharmaceutical companies, and how many route to pre-existing manufacturer or pharmacy discounts? Please identify the drugs in each category.
9. Which drug pricing agreements between the White House and pharmaceutical companies contain provisions governing the companies’ participation in TrumpRx? Please describe those provisions, including those covering companies’ mandatory or voluntary participation; the inclusion or exclusion of certain patients or products; and companies’ discretion to unilaterally raise prices on the platform.
10. Please describe any policies and procedures related to the Trump Administration’s oversight of patient safety issues associated with the use of TrumpRx products, focusing on the identification and investigation of adverse events associated with gaps in continuity of care (including, for example, product discontinuation, switching between products or sources, and changing in prescription tracking between pharmacies and TrumpRx).

By focusing on these core questions, we believe the GAO can provide Congress and the American people with important details on the actual impact of the Trump Administration’s deals.

Thank you for your attention to this matter.

Sincerely,

A handwritten signature in blue ink that reads "Frank Pallone, Jr." with a stylized flourish at the end.

Frank Pallone, Jr.
Ranking Member

The Honorable Orice Williams Brown
October 27, 2026
Page 4

cc: The Honorable Brett Guthrie
Chairman